---
figid: PMC9271889__MCO2-3-e150-g004
figtitle: 'Autophagy in health and disease: From molecular mechanisms to therapeutic
  target'
organisms:
- Human immunodeficiency virus 1
- Severe acute respiratory syndrome coronavirus 2
- Hepatitis B virus
- Coronaviridae
- unidentified influenza virus
- Betacoronavirus
- Human alphaherpesvirus 2
- Zaire ebolavirus
- Saccharomyces cerevisiae
- Arabidopsis thaliana
- Artemisia annua
- Mus musculus
- Rattus norvegicus
- Drosophila melanogaster
- Caenorhabditis elegans
- Homo sapiens
- Danio rerio
- Mycobacterium tuberculosis
organisms_ner:
- Mus musculus
- Homo sapiens
- Rattus norvegicus
- Danio rerio
- Drosophila melanogaster
- Caenorhabditis elegans
- Saccharomyces cerevisiae S288C
pmcid: PMC9271889
filename: MCO2-3-e150-g004.jpg
figlink: /pmc/articles/PMC9271889/figure/mco2150-fig-0005/
number: F5
caption: Targeting the autophagy‐lysosome pathway as novel therapeutic strategies
  for COVID‐19. The replication cycle of SARS‐CoV‐2 consists of six consecutive steps,
  as well as the cross‐talks of this cycle with the autophagy–lysosome pathway are
  presented. The red boxes indicate that the lysosomotropic agents targeting the autophagy–lysosome
  pathway are under development as therapeutics against COVID‐19
papertitle: 'Autophagy in health and disease: From molecular mechanisms to therapeutic
  target.'
reftext: Guang Lu, et al. MedComm (2020). 2022 Sep;3(3):e150.
year: '2022'
doi: 10.1002/mco2.150
journal_title: MedComm
journal_nlm_ta: MedComm (2020)
publisher_name: John Wiley and Sons Inc.
keywords: autophagy | cancer | cardiovascular diseases | metabolic diseases | neurodegenerative
  diseases | SARS‐CoV‐2
automl_pathway: 0.926131
figid_alias: PMC9271889__F5
figtype: Figure
redirect_from: /figures/PMC9271889__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9271889__MCO2-3-e150-g004.html
  '@type': Dataset
  description: Targeting the autophagy‐lysosome pathway as novel therapeutic strategies
    for COVID‐19. The replication cycle of SARS‐CoV‐2 consists of six consecutive
    steps, as well as the cross‐talks of this cycle with the autophagy–lysosome pathway
    are presented. The red boxes indicate that the lysosomotropic agents targeting
    the autophagy–lysosome pathway are under development as therapeutics against COVID‐19
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Ulk1
  - Atg12
  - Tmem41b
  - Map1lc3b
  - Ace2
  - Atg16l1
  - Tmub1
  - Rab7
  - Stx17
  - Snap29
  - ULK1
  - ATG12
  - ERVK-9
  - ERVK-11
  - ERVK-19
  - TMEM41B
  - GABARAPL2
  - GABARAPL1
  - ACE2
  - ATG16L1
  - ALPL
  - TMUB1
  - RAB7A
  - RAB7B
  - STX17
  - SNAP29
  - Rab7a
  - ulk1b
  - atg12
  - tmem41b
  - ace2
  - atg16l1
  - rab7a
  - stx17
  - snap29
  - Atg1
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - fab1
  - stas
  - Atg8a
  - Atg8b
  - Ace
  - Syx17
  - ace-2
  - rab-7
  - snap-29
  - ATG8
---
